Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of the American Chemical Society|December 19, 2002
Transition metal-catalyzed hetero-[5 + 2] cycloadditions of cyclopropyl imines and alkynes: dihydroazepines from simple, readily available starting materialsPaul A Wender, Torben M Pedersen, Marc J C ScanioAngewandte Chemie (International Ed. in English)|May 2, 2018
Serial [5+2]/[4+2] Cycloadditions: Facile, Preparative, Multi-Component Syntheses of Polycyclic Compounds from Simple, Readily Available Starting MaterialsPaul A Wender, Gabriel G Gamber, Marc J C ScanioCurrent Topics in Medicinal Chemistry|May 16, 2009
Voltage-gated sodium channel blockers for the treatment of chronic painMark A Matulenko, Marc J C Scanio, Michael E KortThe Journal of Pharmacology and Experimental Therapeutics|December 20, 2007
A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic ratsSteve McGaraughty, Katharine L Chu, Marc J C Scanio, et al.Journal of Medicinal Chemistry|October 4, 2011
Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligandsMarc J C Scanio, Lei Shi, William H Bunnelle, et al.Journal of Medicinal Chemistry|June 26, 2009
Octahydropyrrolo[3,4-c]pyrrole: a diamine scaffold for construction of either alpha4beta2 or alpha7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivityWilliam H Bunnelle, Karin R Tietje, Jennifer M Frost, et al.Bioorganic & Medicinal Chemistry Letters|June 10, 2022
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosisMarc J C Scanio, Xenia B Searle, Bo Liu, et al.ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic FibrosisMarc J C Scanio, Xenia B Searle, Bo Liu, et al.Bioorganic & Medicinal Chemistry|April 18, 2022
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of painMeena V Patel, Hillary M Peltier, Mark A Matulenko, et al.Bioorganic & Medicinal Chemistry|October 23, 2010
Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic painMarc J C Scanio, Lei Shi, Irene Drizin, et al.Pageof 2